The effectiveness and safety of naldemedine in treating opioid-induced constipation among non-cancer adult patients: updated meta-analysis
Naldemedine 0.2 mg is effective for treating OIC in non-cancer patients and is generally well tolerated, with primarily mild-moderate AEs. Further studies should explore long-term safety and comparisons with other PAMORAs.This review was registered in the PROSPERO databases (CRD42023472575).
Authors
- Mohammad M. Alnaeem (ORCID: https://orcid.org/0000-0001-9142-7437)
- Khaled H. Suleiman
Institutions
- Al-Zaytoonah University of Jordan (JO)
Publication Details
- Journal
- Expert Opinion on Drug Safety
- Published
- 2025-12-25
- DOI
- https://doi.org/10.1080/14740338.2025.2610488
- Primary Topic
- Gastrointestinal motility and disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00